Market Research Report
Tyrosine Protein Kinase Mer - Drugs In Development, 2021
|Tyrosine Protein Kinase Mer - Drugs In Development, 2021|
Published: June 30, 2021
Global Markets Direct
Content info: 94 Pages
Delivery time: 1-2 business days
According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 184.108.40.206) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 220.127.116.11) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2021' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 9 and 1 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.